Abstract
Purpose
As some patients show little response to latanoprost, one of the most powerful topical glaucoma medications, we investigated the incidence and clinical profiles of latanoprost nonresponders (LNR) in the Japanese population.
Methods
We examined 62 glaucoma patients (62 eyes) who had received only latanoprost for more than 3 months. Their mean age was 63.8 ± 1.8 years; the mean observation period was 9.7 ± 0.4 months. At 1, 3, 6, and 12 months, their intraocular pressure (IOP) was measured, and the IOP reduction rate (RR) and the rate of LNR, defined as RR of 10% or less, were calculated. We statistically analyzed clinical factors involved in the LNR status of our study population.
Results
At 1, 3, 6, and 12 months, RR was 20.1 ± 2.0%, 18.8 ± 2.3%, 21.1 ± 2.8%, and 23.0 ± 2.6%, respectively. At the same time points, the LNR incidence was 23.1%, 28.1%, 23.5%, and 31.8%, respectively, and significantly higher in patients whose baseline IOP was less than 15 mmHg. Patient sex and age and the glaucoma type played no significant role in the LNR status.
Conclusions
The incidence of LNR in the Japanese population, including normal-tension glaucoma (NTG) patients, is higher than among European or American patients. Only low baseline IOP was a significant clinical factor among LNR. Jpn J Ophthalmol 2006;50:153–157 © Japanese Ophthalmological Society 2006
Similar content being viewed by others
References
CB Camras InstitutionalAuthorNamethe United States Latanoprost Study Group (1996) ArticleTitleComparison of latanoprost and timolol in patients with ocular hypertension and glaucoma Ophthalmology 103 138–147 Occurrence Handle8628544 Occurrence Handle1:STN:280:BymB3MngsFY%3D
CB Camras A Alm P Watson J Stjernshantz InstitutionalAuthorNameThe Latanoprost Study Group (1996) ArticleTitleLatanoprost, a prostaglandin analog, for glaucoma therapy Ophthalmology 103 1916–1924 Occurrence Handle8942890 Occurrence Handle1:STN:280:ByiD1MfjsV0%3D
PG Watson InstitutionalAuthorNamethe Latanoprost Study Group (1998) ArticleTitleTwo years' experience of its use in the United Kingdom Ophthalmology 105 82–87 Occurrence Handle10.1016/S0161-6420(98)91372-0 Occurrence Handle9442782 Occurrence Handle1:STN:280:DyaK1c7gsV2qsQ%3D%3D
M Saito R Takano S Shirato (2001) ArticleTitleEffects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma Am J Ophthalmol 132 485–489 Occurrence Handle10.1016/S0002-9394(01)01096-0 Occurrence Handle11589867 Occurrence Handle1:CAS:528:DC%2BD3MXnt1SgtL4%3D
T Aung TKP Chew C Yip et al. (2001) ArticleTitleA randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension Am J Ophthalmol 131 636–642 Occurrence Handle11336940 Occurrence Handle1:CAS:528:DC%2BD3MXjtFGmsL4%3D
WE Sponsel G Paris Y Trigo M Pena (2002) ArticleTitleComparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma Am J Ophthalmol 134 552–559 Occurrence Handle10.1016/S0002-9394(02)01643-4 Occurrence Handle12383812 Occurrence Handle1:CAS:528:DC%2BD38Xns1Shsbc%3D
R Sihota R Saxena HC Agarwal RM Pandey V Gulati (2003) ArticleTitlePeak pressures: crossover study of timolol and latanoprost Eur J Ophthalmol 13 546–552 Occurrence Handle12948313 Occurrence Handle1:STN:280:DC%2BD3svgvV2qtQ%3D%3D
LM Bernard R Althin R Dhawan DT Grima A Lam S Aballea (2003) ArticleTitleClinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France Eur J Ophthalmol 13 S30–43 Occurrence Handle12948051
PG Watson (1999) ArticleTitleLatanoprost in the treatment of glaucoma and ocular hypertension Drugs Today (Barc) 35 449–459 Occurrence Handle1:CAS:528:DyaK1MXlt1Wqu7Y%3D
H Tsukamoto HK Mishima Y Kitazawa M Araie H Abe A Negi InstitutionalAuthorNameGlaucoma Study Group (2002) ArticleTitleA comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension Glaucoma 11 497–501
WJ Scherer (2002) ArticleTitleRetrospective review of nonresponders to latanoprost J Ocul Pharmacol Ther 18 287–291 Occurrence Handle10.1089/108076802760116205 Occurrence Handle12099549 Occurrence Handle1:CAS:528:DC%2BD38XltVyjt78%3D
RD Williams (2002) ArticleTitleEfficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost Adv Ther 19 275–281 Occurrence Handle12665048 Occurrence Handle1:CAS:528:DC%2BD3sXit1Gqu7k%3D
HB DuBiner M Moroz AM Shapiro MS Dirks (2001) ArticleTitleA comparison of the efficacy and tolerability of brimonidine and latanoprost: a three-month, multicenter, randomized, double-masked, parallel-group trial Clin Ther 23 1969–1983 Occurrence Handle10.1016/S0149-2918(01)80150-8 Occurrence Handle11813932 Occurrence Handle1:CAS:528:DC%2BD38XhtVyltLg%3D
AM Garcia RP Garcia (2002) ArticleTitleEfficacia del latanoprost en monotherapia en el tratamiento del glaucoma primario de anglo abierto Arch Soc Esp Oftalmol 77 269–274
T Krupin PR Singer J Perlmutter AE Kolker B Becker (1981) ArticleTitleOne-hour intraocular pressure response to timolol. Lack of correlation with long-term response Arch Ophthalmol 99 840–841 Occurrence Handle7236087 Occurrence Handle1:STN:280:Bi6B3cnotVQ%3D
RJ Uusitalo A Palkama (1989) ArticleTitleLong-term evaluation of timolol Acta Ophthalmol (Copenh) 67 573–581 Occurrence Handle1:STN:280:By%2BD2s7ltVM%3D
B Becker DH Shin (1976) ArticleTitleResponse to topical epinephrine. A practical prognostic test in patients with ocular hypertension Arch Ophthalmol 94 2057–2058 Occurrence Handle999549 Occurrence Handle1:STN:280:CSiD28vpvVY%3D
M Detry-Morel F De Hoste (1997) ArticleTitleTreatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium-term retrospective experience with dorzolamido Bull Soc Belge Ophtalmol 267 157–166 Occurrence Handle9745826 Occurrence Handle1:STN:280:DyaK1cvhvVenug%3D%3D
SA Gandolfi L Cimino (2003) ArticleTitleEffect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost Ophthalmology 110 609–614 Occurrence Handle12623831
LB Enyedi SF Freedman EG Buckley (1999) ArticleTitleThe effectiveness of latanoprost for the treatment of pediatric glaucoma J AAPOS 3 33–39 Occurrence Handle10071899 Occurrence Handle1:STN:280:DyaK1M7ntVWitw%3D%3D
PA Netland T Landry EK Sullivan InstitutionalAuthorNamethe Travoprost Study Group et al. (2001) ArticleTitleTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 132 472–484 Occurrence Handle10.1016/S0002-9394(01)01177-1 Occurrence Handle11589866 Occurrence Handle1:CAS:528:DC%2BD3MXnt1Sgt7c%3D
Y Shiose Y Kitazawa S Tsukahara et al. (1991) ArticleTitleEpidemiology of glaucoma in Japan—a nationwide glaucoma survey Jpn J Ophthalmol 35 133–155 Occurrence Handle1779484 Occurrence Handle1:STN:280:By2C3sblslQ%3D
A Iwase Y Suzuki M Araie et al. (2004) ArticleTitleThe prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study Ophthalmology 111 1641–1648 Occurrence Handle15350316
AH Rulo EL Greve HC Geijssen PF Hoyng (1996) ArticleTitleReduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma Ophthalmology 103 1276–1282 Occurrence Handle8764799 Occurrence Handle1:STN:280:BymA2M%2FivFQ%3D
A Bhandari DP Crabb D Poinoosawmy FW Fitzke RA Hitchings BN Noureddin (1997) ArticleTitleEffect of surgery on visual field progression in normal-tension glaucoma Ophthalmology 104 1131–1137 Occurrence Handle9224466 Occurrence Handle1:STN:280:ByiA28jns1c%3D
N Koseki M Araie S Shirato S Yamamoto (1997) ArticleTitleEffect of trabeculectomy on visual field performance in central 30 degree field in progressive normal-tension glaucoma Ophthalmology 104 197–201 Occurrence Handle9052622 Occurrence Handle1:STN:280:ByiB3crhtFE%3D
T Shigeeda A Tomidokoro M Araie N Koseki S Yamamoto (2002) ArticleTitleLong-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma Ophthalmology 109 766–770 Occurrence Handle10.1016/S0161-6420(01)01009-0 Occurrence Handle11927438
L Daugeliene T Yamamoto Y Kitazawa (1999) ArticleTitleRisk factors for visual field damage progression in normal-tension glaucoma eyes Graefes Arch Clin Exp Ophthalmol 237 105–108 Occurrence Handle10.1007/s004170050203 Occurrence Handle9987625 Occurrence Handle1:STN:280:DyaK1M7kt1Squg%3D%3D
InstitutionalAuthorNameThe Collaborative Normal-Tension Glaucoma Study Group (1998) ArticleTitleComparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am J Ophthalmol 126 487–497
J Stjernschantz B Resul (1992) ArticleTitlePhenyl-substituted prostaglandin analogs for glaucoma treatment Drugs Future 17 691–704
B Resul J Stjernschantz K No et al. (1993) ArticleTitlePhenyl-substituted prostaglandin: potent and selective antiglaucoma agents J Med Chem 36 243–248 Occurrence Handle8423596 Occurrence Handle1:CAS:528:DyaK3sXhtVWlur0%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ikeda, Y., Mori, K., Ishibashi, T. et al. Latanoprost Nonresponders with Open-Angle Glaucoma in the Japanese Population. Jpn J Ophthalmol 50, 153–157 (2006). https://doi.org/10.1007/s10384-005-0293-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10384-005-0293-x